Jenna Wong

Jenna Wong

Auto-generated profile, based on publicly available information

Jenna Wong

Biotheranostics Inc., A Hologic Company, San Diego, California

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2024 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
JBJohn M.S. Bartlett
John M.S. Bartlett
KXKeying Xu
Keying Xu
JWJenna Wong
Jenna Wong
GPGreg Pond
Greg Pond
YZYi Zhang
Yi Zhang
JBJane Bayani
Jane Bayani
Purpose: Patients with early-stage hormone receptor–positive (HR+) breast cancer face a prolonged risk of recurrence even after adjuvant endocrine therapy. The Breast Cancer Index (BCI) is significantly prognostic for overall (0–10 years) and late (5–10 years) distant recurrence (DR) risk in N0 and N1 patients. Here, BCI prognostic performance was evaluated in HR+ postmenopausal women from the Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial. Experimental Design: 3,544 patients were included in the analysis (N = 1,519 N0, N = 2,025 N+). BCI risk groups were calculated using pre-specified cutoff points. Kaplan–Meier analyses and log-rank tests were used to assess the prognostic significance of BCI risk groups based on DR. Hazard ratios (HR) and confidence intervals (CI) were calculated using Cox models with and without clinical covariates. Results: For overall 10-year DR, BCI was significantly prognostic in Ni0 (N = 1,196) and N1 (N = 1,234) patients who did not receive prior chemotherapy (P < 0.001). In patients who were DR-free for 5 years, 10-year late DR rates for low- and high-risk groups were 5.4% and 9.3% (N0 cohort, N = 1,285) and 4.8% and 12.2% (N1 cohort, N = 1,625) with multivariate HRs of 2.25 (95% CI, 1.30–3.88; P = 0.004) and 2.67 (95% CI, 1.53–4.63; P < 0.001), respectively. Late DR performance was substantially improved using previously optimized cutoff points, identifying BCI low-risk groups with even lower 10-year late DR rates of 3.8% and 2.7% in N0 and N1 patients, respectively. Conclusions: The TEAM trial represents the largest prognostic validation study for BCI to date and provides a more representative assessment of late DR risk to guide individualized treatment decision-making for HR+ patients with early-stage breast cancer.

27 March 2025 in Clinical Cancer Research
Verified
Journal Article
Open access
MJMarie-France Jilderda
Marie-France Jilderda
YZYi Zhang
Yi Zhang
VRValerie Rebattu
Valerie Rebattu
RSRanelle Salunga
Ranelle Salunga
WMWilma Mesker
Wilma Mesker
GLGerrit-Jan Liefers
Gerrit-Jan Liefers
Purpose: This study assessed the prognostic ability of the breast cancer index (BCI) to identify patients at a minimal risk (<5%) of 10-year distant recurrence (DR) who are unlikely to benefit from adjuvant endocrine therapy. Experimental Design: This prospective translational study included postmenopausal patients with early-stage, hormone receptor–positive N0 breast cancer from the Stockholm (STO-3) trial who underwent surgery alone (“untreated”) or surgery plus adjuvant tamoxifen (“treated”) and from the Netherlands Cancer Registry (surgery alone). The primary endpoint was time to DR. An adjusted BCI model with an additional cutpoint was developed, which stratified patients into four prognostic risk groups. Results: Across cohorts, 16% to 22% of patients were classified as minimal risk of 10-year DR. In the Stockholm untreated cohort (n = 283), risks in the minimal-, low-, intermediate-, and high-risk groups were 2.3%, 15.5% [hazard ratio, 4.71 (95% confidence interval, 1.09–20.29) vs. minimal risk], 19.8% [6.97 (1.61–30.18)], and 35.9% [13.21 (3.07–56.76)], respectively (P < 0.001). In the Stockholm treated cohort (n = 317), risks were 4.3%, 5.0% [1.16 (0.35–3.85)], 11.7% [2.45 (0.74–8.14)], and 21.1% [5.27 (1.72–16.16); P < 0.001]. In the Netherlands Cancer Registry cohort (n = 1245), risks were 4.5%, 7.5% [subdistribution hazard ratio, 1.67 (95% confidence interval, 0.81–3.45)], 10.3% [2.40 (1.14–5.03)], and 13.1% [3.13 (1.50–6.55); P = 0.005]. BCI risk scores provided additional independent information over standard prognostic factors (likelihood ratio, χ2 = 7.98; P = 0.004). Conclusions: The adjusted BCI model identified women with early-stage, hormone receptor–positive N0 breast cancer at a minimal risk of DR who may consider de-escalating adjuvant endocrine therapy.

15 April 2024
Verified
Other
Open access
JBJohn M.S. Bartlett
John M.S. Bartlett
KXKeying Xu
Keying Xu
JWJenna Wong
Jenna Wong
GPGreg Pond
Greg Pond
YZYi Zhang
Yi Zhang
JBJane Bayani
Jane Bayani
Supplemental Figure 1. Continuous risk curves of BCI and BCIN+ for overall 10-year DR in patients who did not receive adjuvant chemotherapy. A: risk of overall 10-year DR as a function of continuous BCI for N0 patients (N=1196); B: risk of overall 10-year DR as a function of continuous BCIN+ for N1 patients (N=1234); C: risk of overall 10-year DR as a function of continuous BCI for N0 HER2- patients (N=978); D: risk of overall 10-year DR as a function of continuous BCIN+ for N1 HER2- patients (N=1067).

15 April 2024
Verified
Other
Open access
JBJohn M.S. Bartlett
John M.S. Bartlett
KXKeying Xu
Keying Xu
JWJenna Wong
Jenna Wong
GPGreg Pond
Greg Pond
YZYi Zhang
Yi Zhang
JBJane Bayani
Jane Bayani
Supplemental Table 2. Distribution of patients as defined by BCI prognostic (BCI/BCIN+) and BCI predictive (BCI (H/I)).

15 April 2024
Verified
Other
Open access
JBJohn M.S. Bartlett
John M.S. Bartlett
KXKeying Xu
Keying Xu
JWJenna Wong
Jenna Wong
GPGreg Pond
Greg Pond
YZYi Zhang
Yi Zhang
JBJane Bayani
Jane Bayani
Purpose:Patients with early-stage hormone receptor–positive (HR+) breast cancer face a prolonged risk of recurrence even after adjuvant endocrine therapy. The Breast Cancer Index (BCI) is significantly prognostic for overall (0–10 years) and late (5–10 years) distant recurrence (DR) risk in N0 and N1 patients. Here, BCI prognostic performance was evaluated in HR+ postmenopausal women from the Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial.Experimental Design:3,544 patients were included in the analysis (N = 1,519 N0, N = 2,025 N+). BCI risk groups were calculated using pre-specified cutoff points. Kaplan–Meier analyses and log-rank tests were used to assess the prognostic significance of BCI risk groups based on DR. Hazard ratios (HR) and confidence intervals (CI) were calculated using Cox models with and without clinical covariates.Results:For overall 10-year DR, BCI was significantly prognostic in Ni0 (N = 1,196) and N1 (N = 1,234) patients who did not receive prior chemotherapy (P < 0.001). In patients who were DR-free for 5 years, 10-year late DR rates for low- and high-risk groups were 5.4% and 9.3% (N0 cohort, N = 1,285) and 4.8% and 12.2% (N1 cohort, N = 1,625) with multivariate HRs of 2.25 (95% CI, 1.30–3.88; P = 0.004) and 2.67 (95% CI, 1.53–4.63; P < 0.001), respectively. Late DR performance was substantially improved using previously optimized cutoff points, identifying BCI low-risk groups with even lower 10-year late DR rates of 3.8% and 2.7% in N0 and N1 patients, respectively.Conclusions:The TEAM trial represents the largest prognostic validation study for BCI to date and provides a more representative assessment of late DR risk to guide individualized treatment decision-making for HR+ patients with early-stage breast cancer.

3 June 2025
Verified
Other
Open access
MJMarie-France Jilderda
Marie-France Jilderda
YZYi Zhang
Yi Zhang
VRValerie Rebattu
Valerie Rebattu
RSRanelle Salunga
Ranelle Salunga
WMWilma Mesker
Wilma Mesker
GLGerrit-Jan Liefers
Gerrit-Jan Liefers
Purpose:This study assessed the prognostic ability of the breast cancer index (BCI) to identify patients at a minimal risk (<5%) of 10-year distant recurrence (DR) who are unlikely to benefit from adjuvant endocrine therapy.Experimental Design:This prospective translational study included postmenopausal patients with early-stage, hormone receptor–positive N0 breast cancer from the Stockholm (STO-3) trial who underwent surgery alone (“untreated”) or surgery plus adjuvant tamoxifen (“treated”) and from the Netherlands Cancer Registry (surgery alone). The primary endpoint was time to DR. An adjusted BCI model with an additional cutpoint was developed, which stratified patients into four prognostic risk groups.Results:Across cohorts, 16% to 22% of patients were classified as minimal risk of 10-year DR. In the Stockholm untreated cohort (n = 283), risks in the minimal-, low-, intermediate-, and high-risk groups were 2.3%, 15.5% [hazard ratio, 4.71 (95% confidence interval, 1.09–20.29) vs. minimal risk], 19.8% [6.97 (1.61–30.18)], and 35.9% [13.21 (3.07–56.76)], respectively (P < 0.001). In the Stockholm treated cohort (n = 317), risks were 4.3%, 5.0% [1.16 (0.35–3.85)], 11.7% [2.45 (0.74–8.14)], and 21.1% [5.27 (1.72–16.16); P < 0.001]. In the Netherlands Cancer Registry cohort (n = 1245), risks were 4.5%, 7.5% [subdistribution hazard ratio, 1.67 (95% confidence interval, 0.81–3.45)], 10.3% [2.40 (1.14–5.03)], and 13.1% [3.13 (1.50–6.55); P = 0.005]. BCI risk scores provided additional independent information over standard prognostic factors (likelihood ratio, χ2 = 7.98; P = 0.004).Conclusions:The adjusted BCI model identified women with early-stage, hormone receptor–positive N0 breast cancer at a minimal risk of DR who may consider de-escalating adjuvant endocrine therapy.